Med by Cell Press

In the July issue of #Med, DeRidder et al. develop a closed-loop automated drug infusion regulator (CLAUDIA) system for personalized dosing of chemotherapy. Chemotherapies are currently dosed based on a patient’s height and weight, using an equation from 1916 to estimate their body surface area. This method leads to variability in pharmacokinetics, potentially causing increased toxicities and decreased efficacy. Personalized dosing could improve the patient’s experience by ensuring the drug reaches the target concentration regardless of other factors, reducing side effects and increasing drug efficacy. The cover illustration depicts a positive treatment experience, with patients walking unbothered by their personalized chemotherapy dose represented by colorful IV bags floating like balloons. Recovery is gentler, and daily life is less impacted by chemotherapy. Explore the issue: https://lnkd.in/ehSgKZTp   Massachusetts Institute of Technology Giovanni Traverso

The 32-month open-label study LILAC-2 evaluated trofinetide in Rett syndrome, showing continued improvement in symptoms without new safety concerns. Caregivers reported satisfaction with trofinetide, noting improvements in patient communication, engagement, and independent movement. Trofinetide demonstrated efficacy and a manageable safety profile in the long-term treatment of Rett syndrome, highlighting its potential as a valuable therapeutic option for patients with this rare neurodevelopmental disorder. James M. Youakim, Acadia Pharmaceuticals Inc. #RettSyndrome #Trofinetide #LILAC2 #NeurodevelopmentalDisorder #LongTermTreatment #PatientCare https://lnkd.in/dn3m2VV3

ABO1020 is a novel mRNA vaccine that demonstrates efficacy against symptomatic COVID-19 in a large international phase 3 clinical trials involving 14,138 adults. Even though ABO1020 was designed based on Omicron variant BA.4/5, it successfully induced protective immunity against more variants, including XBB.1.5, in both elderly and younger adults. Vaccinations with ABO1020 were safe and well tolerated. #ABO1020 #COVID19vaccine #Efficacy #NeutralizingAntibodies #PublicHealth #ClinicalTrials https://lnkd.in/duRhTRpR

#Med, #CancerCell, and #CellReportsMedicine have put together a #clinicaloncology collection that we're excited to share! You can register to receive it in your inbox here: https://hubs.li/Q02GmQYd0

Read the latest open-access Perspective by Javier Martínez-Picado and colleagues from IrsiCaixa on exceptional elite controllers - a rare group of individuals with HIV-1 who can naturally suppress the virus to undetectable levels without requiring antiretroviral therapy for extended periods, often over 25 years. These individuals have unique genetic, virological, and immunological features that make them a valuable model for studying potential functional cures for HIV-1. #EliteControllers #HIVResearch https://lnkd.in/ezesvu5Q

Online Now: Functional modification of gut bacteria for disease diagnosis and treatment http://dlvr.it/T9cjd3

Recent advancements in the treatment of obstructive hypertrophic cardiomyopathy have centered on the development of cardiac myosin inhibitors, such as mavacamten and aficamten. Read the latest Commentary by Milind Desai MD MBA and Eugene Braunwald for an overview of the key research findings, similarities and potential distinctions observed in clinical trials investigating aficamten and mavacamten. https://lnkd.in/eq2NbDJG #HypertrophicCardiomyopathy #CardiacMyosinInhibitors #Aficamten #Mavacamten #SEQUOIAHCM #EXPLORERHCM #VALORHCM #ClinicalTrials

Online Now: Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer http://dlvr.it/T9VwjJ

#CellPress journals are now on LinkedIn! Follow their pages for updates on new research, conference attendance, initiatives, and more. Links below: Cell by Cell Press https://lnkd.in/edVehas6 Cell Reports Sustainability https://lnkd.in/eB-ipdV8 Chem by Cell Press https://lnkd.in/eU3Hd_5a Med by Cell Press https://lnkd.in/eTD6vyCk iScience https://lnkd.in/eyFsjGaZ Trends in Biotechnology https://lnkd.in/exkFU737 More journals to come!

Researchers from Peking Union Medical College analyzed longitudinal cohort data from over 4000 SLE patients and found that those with serologically active but clinically inactive lupus (SACQ) can be divided into three subgroups. These subgroups have different risks of future flares and organ damage. This new understanding could help doctors tailor treatments for each patient, potentially improving long-term outcomes. #lupusresearch #SACQ #SLE https://lnkd.in/gsvWESAE